Ikarian Capital’s Praxis Precision Medicines PRAX Stock Holding History

Ikarian Capital’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-100,000	Closed	-$5.3M	–	209
2025 Q3	$5.3M	Sell	100,000 -142,400	-59%	-$6.9M	0.54%	42
2025 Q2	$10.2M	Buy	+242,400	New	+$9.23M	1.96%	16
2024 Q3	–	Sell	-3,000	Closed	-$12.4M	–	166
2024 Q2	$12.4M	Sell	3,000 -18,800	-86%	-$888K	2.16%	15
2024 Q1	$1.33M	Buy	+21,800	New	+$978K	0.15%	99
2022 Q4	–	Sell	-4,947	Closed	-$168K	–	100
2022 Q3	$168K	Sell	4,947 -2,200	-31%	-$110K	0.03%	95
2022 Q2	$263K	Buy	+7,147	New	+$763K	0.05%	112

Other funds holding PRAX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Ikarian Capital's PRAX Position: Q1 2026 in Review

Ikarian Capital reduced its Praxis Precision Medicines (PRAX) stake by 17% in Q1 2026, selling an estimated $4.64M and leaving 71,581 shares worth $23.1M. The position accounts for 1.87% of the portfolio, ranked #13.

Ikarian Capital first reported a position in PRAX in Q4 2020 and has held it in 10 quarters since. The position peaked at $25.5M in Q4 2025. 289 funds tracked by Wall St. Rank hold PRAX as of Q1 2026.

Ikarian Capital held 71,581 shares of Praxis Precision Medicines worth $23.1M as of Q1 2026.
Ikarian Capital sold 15,000 Praxis Precision Medicines shares in Q1 2026, an estimated $4.64M.
Praxis Precision Medicines made up 1.87% of Ikarian Capital's portfolio in Q1 2026, its #13 holding.
Ikarian Capital first reported a position in Praxis Precision Medicines in Q4 2020 and has held it in 10 quarters since.
Ikarian Capital's Praxis Precision Medicines position peaked at $25.5M in Q4 2025.
289 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q1 2026.

Based on Ikarian Capital's 13F filing for Q1 2026, filed 15 May 2026.